Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia

Marta Caballero-Ávila, Rodrigo Álvarez-Velasco, Esther Moga, Ricard Rojas-Garcia, Janina Turon-Sans, Luis Querol, Montse Olivé, David Reyes-Leiva, Isabel Illa, Eduard Gallardo, Elena Cortés-Vicente*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)


The aim of this study is to evaluate the long-term efficacy, safety, and impact on immunoglobulin G (IgG) levels of rituximab in patients with myasthenia gravis (MG). A retrospective, observational study of drug-refractory MG patients treated with rituximab was done. The MG Foundation of America postintervention status (MGFA-PIS) was used to evaluate clinical response. Serum IgG levels were determined at baseline and post-treatment. Hypogammaglobulinemia was defined as IgG<7g/L. Thirty patients were included, 12 with anti-MuSK and 18 with anti-AChR antibodies. Mean (SD) follow-up was 85.5 (48) months. All 12 MuSK+ patients but only six (33%) AChR+ patients achieved minimal manifestations or remission (p<0.01). Nine severe infections were observed in five patients (17%). One patient was diagnosed with progressive multifocal leukoencephalopathy. At baseline, two patients (2/24; 8%) had hypogammaglobulinemia. During follow-up, hypogammaglobulinemia was observed in 60% (3/5) of patients who developed an infection and in 33% (7/21) who did not. Two of these patients died of infection-related complications. This study supports the effectiveness of rituximab in patients with MG, especially those with anti-MuSK antibodies. Severe infections may appear after rituximab treatment and hypogammaglobulinemia might play a role on it. A standard protocol would be needed to closely monitor IgG levels in MG patients treated with rituximab.

Original languageEnglish
Pages (from-to)664-671
Number of pages8
JournalNeuromuscular Disorders
Issue number8
Publication statusPublished - 1 Aug 2022


  • Adverse events
  • Autoimmune
  • Hypogammaglobulinemia
  • Infection
  • Myasthenia gravis
  • Rituximab
  • Humans
  • Immunoglobulin G/therapeutic use
  • Immunologic Factors/adverse effects
  • Agammaglobulinemia/chemically induced
  • Retrospective Studies
  • Myasthenia Gravis
  • Receptors, Cholinergic
  • Rituximab/adverse effects


Dive into the research topics of 'Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia'. Together they form a unique fingerprint.

Cite this